Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users

Journal of Pharmaceutical and Biomedical Analysis

Volumn 44, Issue 1, 2007, Pages 188-195

  DiFrancesco, Robin ^a   Fischl, Margaret A ^b   Donnelly, Julie ^a   Zingman, Barry S ^c   McCance Katz, Elinore F ^d   Moody, David E ^e   Reichman, Richard C ^f   Gripshover, Barbara ^g   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antiretrovirals; Buprenorphine; HIV; Plasma concentration monitoring; Substance abuse treatment

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BUPRENORPHINE; CITALOPRAM; DRUG METABOLITE; EFAVIRENZ; FLUCONAZOLE; IMIQUIMOD; KETOCONAZOLE; LAMIVUDINE; LISINOPRIL; NORBUPRENORPHINE; RITONAVIR; SULFAMETHOXAZOLE; TENOFOVIR; TESTOSTERONE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VENLAFAXINE; ZIDOVUDINE; ZOLPIDEM TARTRATE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RETENTION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SPECTROMETRY; PRIORITY JOURNAL; SUBSTANCE ABUSE;

BENZOXAZINES; BIOLOGICAL ASSAY; BUPRENORPHINE; CALIBRATION; CHROMATOGRAPHY, LIQUID; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; PYRIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE-RELATED DISORDERS; TANDEM MASS SPECTROMETRY;

EID: 34047260735     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.02.014     Document Type: Article

References (33)

1. Bickel W.K., and Amass L. Exp. Clin. Psychopharmacol. 3 (1995) 477-489
2. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. N. Engl. J. Med. 343 (2000) 1290-1297
3. Kuhlman Jr. J.J., Levine B., Johnson R.E., Fudala P.J., and Cone E.J. Addiction 93 (1998) 549-559
4. McCance-Katz E.F. Harv. Rev. Psych. 12 (2004) 321-338
5. McCance-Katz E.F., et al. Clin. Infect. Dis. 4 (2006) S224-S234
6. McCance-Katz E.F., Moody D.E., Smith P.F., Morse G.D., Friedland G.D., Pade P., Baker J., Alvanzo A., Jatlow P., and Rainey P.M. Clin. Infect. Dis. 4 (2006) S235-S246
7. E.F. McCance-Katz, P. Pade, G. Friedland, G.D. Morse, D. Moody, P. Rainey, efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals (Abstract 653), Boston, MA, 2005.
8. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clin. Pharmacol. Ther. 55 (1994) 569-580
9. Para M.F., et al. Antimicrob. Agents Chemother. 43 (1999) 1373-1378
10. Bruce R.D., McCance-Katz E., Kharasch E.D., Moody D.E., and Morse G.D. Clin. Infect. Dis. 4 (2006) S216-S223
11. Cowan A. Int. J. Clin. Pract. Suppl. (2003) 3-8 discussion 23-24
12. Iribarne C., Picart D., Dreano Y., Bail J.P., and Berthou F. Life Sci. 60 (1997) 1953-1964
13. Morse G.D., Fischl M.A., Shelton M.J., Cox S.R., Driver M., DeRemer M., and Freimuth W.W. Antimicrob. Agents Chemother. 41 (1997) 169-174
14. Clarke S.M., Mulcahy F.M., Tjia J., Reynolds H.E., Gibbons S.E., Barry M.G., and Back D.J. Br. J. Clin. Pharmacol. 51 (2001) 213-217
15. Clarke S.M., Mulcahy F.M., Tjia J., Reynolds H.E., Gibbons S.E., Barry M.G., and Back D.J. Clin. Infect. Dis. 33 (2001) 1595-1597
16. B. Booker, P. Smith, A. Forrest, R. DiFrancesco, G. Morse, P. Cottone, M. Murphy, E. McCance-Katz, Lack of effect of methadone (MET) on the pharmacokinetics of delavirdine (DLV) and N-Delavirdine (NDLV) (Abstract A-490), Chicago, IL, 2001.
17. Dyer K.R., Foster D.J., White J.M., Somogyi A.A., Menelaou A., and Bochner F. Clin. Pharmacol. Ther. 65 (1999) 685-694
18. McCance-Katz E.F., Rainey P., Smith P., Morse G.D., Friedland G.H., Boyarsky B., Gourevitch M., and Jatlow P. Am. J. Addict. 15 1 (2006) 23-34
19. McCance-Katz E.F., Rainey P.M., Friedland G., and Jatlow P. Clin. Infect. Dis. 37 (2003) 476-482
20. McCance-Katz E.F., Rainey P.M., Smith P., Morse G.D., Friedland G., Gourevitch M., and Jatlow P. Am. J. Addict. 13 (2004) 163-180
21. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. J. Clin. Psychopharmacol. 16 (1996) 58-67
22. McCance-Katz E.F., Rainey P.M., Friedland G., Kosten T.R., and Jatlow P. Am. J. Addict. 10 (2001) 296-307
23. McCance-Katz E.F., Rainey P.M., Jatlow P., and Friedland G. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 18 (1998) 435-443
24. P. Smith, E. McCance-Katz, J. Sarlo, R. DiFrancecso, G.D. Morse, Methadone increases ritonavir exposure when administered alone but not lopinavir/ritonavir combination (Abstract H-2000), Chicago, IL, 2003.
25. Keil K., Frerichs V.A., DiFrancesco R., and Morse G. Ther. Drug Monit. 25 (2003) 340-346
26. Keil K., Difrancesco R., and Morse G.D. Ther. Drug Monit. 28 (2006) 512-516
27. Ceccato A., Klinkenberg R., Hubert P., and Streel B. J. Pharm. Biomed. Anal. 32 (2003) 619-631
28. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., and Foltz R.L. Anal. Biochem. 306 (2002) 31-39
29. Musshoff F., Trafkowski J., Kuepper U., and Madea B. J. Mass Spectrom. 41 (2006) 633-640
30. Polettini A., and Huestis M.A. J. Chromatogr. B. Biomed. Sci. Appl. 754 (2001) 447-459
31. FDA GUIDANCE FOR INDUSTRY. Bioanalytical Method Validation (available at http://www.fda.gov/cder/guidance/4252fnl.pdf), US Department of Health and Human Services, FDA, CDER, CVM, May, 2001.
32. Fed. Regist. 57 (1992) 7002-186.
33. Bruce R.D., and Altice F.L. Aids 20 (2006) 783-784